Skip to content
Sunday 9 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Astrazeneca

  • Sage advisers: Protection given from Covid vaccine ‘highly likely’ to wane over time

    July 30, 2021

    Vaccine campaigns will likely have to continue for many years as the Covid immunity induced by the shots is ‘highly likely to wane over time’, according to scientific advisers to the government. “It is highly likely that vaccine induced immunity to SARS-CoV-2 infection, and potentiallysevere disease (but probably to a lesser extent) will wane over [...]

  • Astrazeneca mulls offloading Covid vaccines unit even as total revenues soar above $15bn

    July 29, 2021

    UK-listed Covid vaccine maker Astrazeneca today admitted it’s considering offloading its vaccines unit even as it cheered a 23 per cent revenue rise to $15.5bn for the first half of 2021 – boosted in part by orders for the preventative measure. A senior executive confirmed to Reuters that it is reviewing the future of the [...]

  • CMA green light: £28bn AstraZeneca and Alexion deal to close late July

    July 14, 2021

    The UK competition watchdog has cleared vaccine maker AstraZeneca’s £28bn bid for rival Alexion, which has been confirmed to close on 21 July. First announced in December last year, the deal is intended to bolster AstraZeneca’s immunology capabilities by adding Alexion’s technology platforms. European Union regulators gave the deal the green light last week. Despite [...]

  • EU regulators clear Astrazeneca’s £28bn takeover of rival Alexion

    July 6, 2021

    European regulators have cleared Astrazeneca’s £28bn takeover of rival Alexion Pharmaceuticals, the British company announced today. The deal, first agreed in December, will give Astrazeneca access to five new drugs and more than a dozen in Alexion’s pipeline. Astra said the clearance from Brussels was an important step towards completed its buyout of the New [...]

  • Pfizer and Moderna vaccine supply limits pace of jab rollout

    June 30, 2021

    There are not enough Pfizer and Moderna vaccines being supplied to reduce the eight week interval between doses, according to analysts. “It appears from the data available that Pfizer and Moderna supplies are the pace-limiting factor,” Matt Linley, an analyst at Airfinity, a data company tracking the vaccine rollout, told The Times. Last month, the [...]

  • UK researchers identify level of antibodies needed to prevent symptomatic Covid-19

    June 24, 2021

    Scientists at the University of Oxford said the results of their research could help speed up new vaccine development. Oxford-based medical researchers have today released a new study indentifying the level of antibodies required to prevent symptomatic Covid – referred to as the “correlates of protection”. Their findings could serve as a huge breakthrough in [...]

  • AstraZeneca claims victory over EU in vaccine deliveries case, but will be fined for late supplies

    June 18, 2021

    AstraZeneca claims victory over EU in vaccine deliveries case

  • CureVac shares plunge after Covid vaccine falls short in clinical trial

    June 17, 2021

    The German biotech lost more than half its value after a preliminary analysis of late-stage trials found its Covid-19 vaccine was only 47 per cent effective. CureVac’s disappointing mRNA vaccine trial results call into question its future contribution to the global vaccination effort. The interim analysis of the jab’s trials found that it was one [...]

  • AstraZeneca and Alexion swap senior staff ahead of $39bn deal close

    June 4, 2021

    Drugmaker AstraZeneca has poached Alexion Pharmaceutical’s chief financial officer ahead of its acquisition, as the pharma firms shuffle their senior staff. Joining with an £850,000 base salary, Aradhana Sarin will join when the deal closes as both an executive director and chief financial officer if the pharmaceutical firm’s deal for Alexion Pharmaceuticals goes to plan. [...]

  • CMA and EU antitrust watchdogs eye AstraZeneca’s $39bn Alexion deal

    June 1, 2021

    EU antitrust watchdogs and are set to decide by this weekend whether to approve AstraZeneca’s $39bn bid for biopharmaceutical company Alexion, a European Commission filing revealed today. Anglo-Swedish drugmaker AstraZeneca sought approval for the deal on Monday. However, the UK’s competition regulator is reviewing the takeover bid for the US-based pharma firm, until 5 July – [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • …
  • Page 27
  • Next

Trending Articles

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • PwC’s Embankment HQ to get major makeover ahead of Canary Wharf move

  • Family feud: London estate agent Winkworth sues chair over plot with wife to oust son from board

  • As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs

  • A tribute to wine legend Matthew Jukes by his friend Libby Brodie

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook